Study the Effect of Using Levofloxacin with Azithromycin with Oseltamivir in the Treatment of Covid 19 Omicron
Abstract
Background: A study was conducted to investigate the use of levofloxacin, azithromycin, and oseltamivir in the treatment of COVID-19 Omicron. The results showed that this combination therapy reduced hospital stays, improved survival rates, cleared lung pathological changes faster, and reduced the need for invasive mechanical ventilation. Omicron is a highly infectious variant of the coronavirus that has caused a global surge in cases. The WHO is currently assessing the effectiveness of various medications against Omicron, including monoclonal antibody therapy and antiviral drugs. The choice of oseltamivir in this study was based on its success in managing COVID-19. Levofloxacin and azithromycin were included in the treatment protocol due to their effectiveness in treating pneumonia caused by COVID-19. Many hospitals have adopted this treatment protocol. Results: Analysis of forty patients included time spent in the hospital, survival rate, enhanced clearance of lung pathological changes, and requirements for invasive mechanical ventilation. Conclusions: combination therapy significantly improved patient outcomes, evidenced by shorter hospital stays (average of 6.05 days for the treated group vs. 33.68 days for the control group), faster clearance of lung pathology within 1 to 2 months, and increased survival rates. The treatment also reduced the need for invasive mechanical ventilation.
Read the paper
Related studies
- Severe clinical outcomes of COVID-19 associated with proton pump inhibitors: a nationwide cohort study with propensity score matching
- Levofloxacin-Induced Tendon Rupture: A Case Report and Review of the Literature
- Association between cord blood 25-hydroxyvitamin D concentrations and respiratory tract infections in the first 6 months of age in a Korean population: a birth cohort study (COCOA)
- Neuroprotective Effects of Epicatechin against Oxidative Stress-Induced Cognitive Impairment: A Systematic Review and Meta-Analysis
- Quality evaluation and in vitro interaction studies between levofloxacin 250mg and diclofenac sodium 50mg tablets
- Molecular Epidemiology of mcr-1 -Positive Polymyxin B-Resistant Escherichia coli Producing Extended-Spectrum β-Lactamase (ESBL) in a Tertiary Hospital in Shandong, China
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.